IL17A and spondyloarthropathy: Another study investigated patients with spondyloarthritis treated with interleukin-17 (IL-17) and/or tumor necrosis factor-alpha (TNFa) Inhibitors (Smetanova et al., 2022), and one was carried out among patients with inflammatory arthritis (Wroński et al., 2022).